MMP13 Antibody | Affinity Biosciences

Product:	MMP13 Antibody
Catalog:	AF5355
Description:	Rabbit polyclonal antibody to MMP13
Application:	WB IHC
Cited expt.:	WB, IHC
Reactivity:	Human, Mouse, Rat
Mol.Wt.:	54 kDa(Observed); 54kD(Calculated).
Uniprot:	P45452
RRID:	AB_2837840

View similar products>>

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific.

Size	Price	Inventory
100ul	$280	In stock
200ul	$350	In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Control Products

#AF5355-BP

MMP13 Peptide

1mg

Related Downloads

Antigen/Blocking Peptide MS Report

Antigen/Blocking Peptide HPLC Report

MSDS

Data Sheet

COA

Protocols

WB Handbook

IHC Protocol

IF/ICC Protocol

Product Info

Source:

Rabbit

Application:

WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:

Human, Mouse, Rat

Clonality:

Polyclonal

Specificity:

MMP13 Antibody detects endogenous levels of total MMP13.

RRID:

AB_2837840
Cite Format: Affinity Biosciences Cat# AF5355, RRID:AB_2837840.

Conjugate:

Unconjugated.

Purification:

The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin.

Storage:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

Alias:

Fold/Unfold

CLG 3; CLG3; Collagenase 3; Collagenase3; MANDP1; Matrix metallopeptidase 13 (collagenase 3); Matrix Metalloproteinase 13; Matrix metalloproteinase-13; MMP 13; MMP-13; Mmp13; MMP13_HUMAN;

Immunogens

Immunogen:

A synthesized peptide derived from human MMP13, corresponding to a region within N-terminal amino acids.

Uniprot:

P45452(MMP13_HUMAN) >>Visit HPA database.

Gene(ID):

MMP13(4322)

Expression:

P45452 MMP13_HUMAN:

Detected in fetal cartilage and calvaria, in chondrocytes of hypertrophic cartilage in vertebrae and in the dorsal end of ribs undergoing ossification, as well as in osteoblasts and periosteal cells below the inner periosteal region of ossified ribs. Detected in chondrocytes from in joint cartilage that have been treated with TNF and IL1B, but not in untreated chondrocytes. Detected in T lymphocytes. Detected in breast carcinoma tissue.

Description:

Defects in MMP13 are the cause of spondyloepimetaphyseal dysplasia Missouri type (SEMD-MO) [MIM:602111]. A bone disease characterized by moderate to severe metaphyseal changes, mild epiphyseal involvement, rhizomelic shortening of the lower limbs with bowing of the femora and/or tibiae, coxa vara, genu varum and pear-shaped vertebrae in childhood. Epimetaphyseal changes improve with age.

Sequence:

P45452 MMP13_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MHPGVLAAFLFLSWTHCRALPLPSGGDEDDLSEEDLQFAERYLRSYYHPTNLAGILKENAASSMTERLREMQSFFGLEVTGKLDDNTLDVMKKPRCGVPDVGEYNVFPRTLKWSKMNLTYRIVNYTPDMTHSEVEKAFKKAFKVWSDVTPLNFTRLHDGIADIMISFGIKEHGDFYPFDGPSGLLAHAFPPGPNYGGDAHFDDDETWTSSSKGYNLFLVAAHEFGHSLGLDHSKDPGALMFPIYTYTGKSHFMLPDDDVQGIQSLYGPGDEDPNPKHPKTPDKCDPSLSLDAITSLRGETMIFKDRFFWRLHPQQVDAELFLTKSFWPELPNRIDAAYEHPSHDLIFIFRGRKFWALNGYDILEGYPKKISELGLPKEVKKISAAVHFEDTGKTLLFSGNQVWRYDDTNHIMDKDYPRLIEEDFPGIGDKVDAVYEKNGYIYFFNGPIQFEYSIWSNRIVRVMPANSILWC

Research Backgrounds

P45452_MMP13_HUMAN

Function:

Plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN. Cleaves triple helical collagens, including type I, type II and type III collagen, but has the highest activity with soluble type II collagen. Can also degrade collagen type IV, type XIV and type X. May also function by activating or degrading key regulatory proteins, such as TGFB1 and CCN2. Plays a role in wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification. Required for normal embryonic bone development and ossification. Plays a role in the healing of bone fractures via endochondral ossification. Plays a role in wound healing, probably by a mechanism that involves proteolytic activation of TGFB1 and degradation of CCN2. Plays a role in keratinocyte migration during wound healing. May play a role in cell migration and in tumor cell invasion.

PTMs:

The proenzyme is activated by removal of the propeptide; this cleavage can be effected by other matrix metalloproteinases, such as MMP2, MMP3 and MMP14 and may involve several cleavage steps. Cleavage can also be autocatalytic, after partial maturation by another protease or after treatment with 4-aminophenylmercuric acetate (APMA) (in vitro).

N-glycosylated.

Tyrosine phosphorylated by PKDCC/VLK.

Subcellular Location:

Secreted>Extracellular space>Extracellular matrix. Secreted.

Tissue Specificity:

Family&Domains:

The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme (By similarity).

The C-terminal region binds to collagen.

Belongs to the peptidase M10A family.

Research Fields

· Organismal Systems > Immune system > IL-17 signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

References

1). Downregulated cytotoxic CD8+ T-cell identifies with the NKG2A-soluble HLA-E axis as a predictive biomarker and potential therapeutic target in keloids. Cellular & molecular immunology, 2022 (PubMed: 35039632) [IF=21.8]

2). Microenvironment-responsive multifunctional enzyme-linked hydrogel for diabetic bone defect regeneration. Nature communications, 2025 (PubMed: 41271711) [IF=16.6]

Application: WB Species: Rat Sample:

Fig. 7: Functional and mechanistic insights of AAT-ZCG for DM bone defects in regulating FoxO1/P53 signaling pathways. A Volcano plot showing differentially expressed genes (DEGs) between experimental and control groups. Red dots indicate up-regulated genes, and blue dots indicate down-regulated genes. B Gene Ontology (GO) enrichment analysis of up-regulated genes. C GO enrichment analysis of down-regulated genes. D Heatmap of the expression levels of DEGs across experimental groups, with specific key genes like FoxO1 highlighted. E Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis of DEGs, identifying significant pathways such as P53 signaling, FoxO1 signaling. F Schematic diagram illustrates the proposed mechanism of AAT-ZCG in activating the forkhead box O1 (FoxO1) and P53 pathways. G Western blot was conducted to evaluate the effects of AAT-ZCG on inflammation and osteogenesis through the FoxO1/P53 signaling pathway. H The effect of AAT-ZCG on the expression of FoxO1, n = 3. I The effect of AAT-ZCG on P53 expression, n = 3. J The effect of AAT-ZCG on the expression of pP53, n = 3. K The effect of AAT-ZCG on the expression of MMP13, n = 3. L The effect of AAT-ZCG on the expression of BMP2, n = 3. M) The effect of AAT-ZCG on the expression of Acp5, n = 3. Data are presented as mean ± SD. Figure 7H-M involved three biological replications (n = 3) and analysis of these experiments’ results were performed using one-way ANOVA. ns, no statistical significance. Statistical significance is indicated as follows: P

3). Opsonization Inveigles Macrophages Engulfing Carrier-Free Bilirubin/JPH203 Nanoparticles to Suppress Inflammation for Osteoarthritis Therapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024 (PubMed: 38593402) [IF=15.1]

4). Interplay between lipid dysregulation and ferroptosis in chondrocytes and the targeted therapy effect of metformin on osteoarthritis. Journal of advanced research, 2025 (PubMed: 38621621) [IF=11.4]

5). Chondrocyte-targeted bilirubin/rapamycin carrier-free nanoparticles alleviate oxidative stress and modulate autophagy for osteoarthritis therapy. Journal of controlled release : official journal of the Controlled Release Society, 2024 (PubMed: 39701459) [IF=10.8]

6). Ultrasound-responsive piezoelectric analgesic microspheres alleviate osteoarthritis pain. Journal of controlled release : official journal of the Controlled Release Society, 2025 (PubMed: 40695377) [IF=10.5]

7). HAMA-SBMA hydrogel with anti-inflammatory properties delivers cartilage organoids, boosting cartilage regeneration. Journal of nanobiotechnology, 2025 (PubMed: 40448111) [IF=10.2]

8). Varespladib-Based Lipid Nanoparticles as Highly Efficient Anti-Inflammatory Agents for Osteoarthritis Treatment. ACS applied materials & interfaces, 2025 (PubMed: 41148155) [IF=8.3]

9). Undercarboxylated OCN Inhibits Chondrocyte Hypertrophy and Osteoarthritis Development through GPRC6A/HIF-1α Cascade. International journal of biological sciences, 2025 (PubMed: 40765832) [IF=8.2]

Application: IHC Species: Mouse Sample:

Figure 1. OCN deficiency leads to increased chondrocyte hypertrophy. (A) Safranin O and fast green staining of representative paraffin sections of femora of the newborn WT mice. The white boxes depict regions of higher magnification of the hypertrophic zone of the growth plate as shown on the right. The arrows depict the hypertrophic chondrocytes. Statistical analysis of the proportion of relatively hypertrophic chondrocytes is shown on the right. (n = 5 mice per group). (B) Immunohistochemistry (IHC) staining of representative paraffin sections of COL2a1, MMP13 and COL10a1 expression in articular cartilage of WT mice and OCN-/- mice. The black boxes depict regions of higher magnification. Statistical analysis is on the right. (n=7 mice per group). (C) Gene expression analysis of hypertrophic markers of primary chondrocytes isolated from WT and OCN-/- newborn mice after monolayer culture. (D) Gene expression analysis of hypertrophic markers of primary chondrocytes isolated from WT and OCN-/- newborn mice after 3D micromass culture for 21 days. (E) IHC staining of representative paraffin sections of MMP13 and COL10a1 expression in chondrocytes of WT and OCN-/- newborn mice after 3D micromass culture for 21 days. The black boxes depict regions of higher magnification. Grade map visualization displayed by the Slide Viewer software is shown below, red represents the intensity of staining (n=3 per group). Statistical analysis is on the right. Scale bar, 100 μm. WT, wild type. OCN-/-, OCN knockout. Student's t-test for two groups, one-way ANOVA for three or more.

10). Microneedles containing Cucumaria frondosa polysaccharides and 3-acetylaconitine exert analgesic, anti-inflammatory and chondroprotective activity for knee osteoarthritis. International journal of biological macromolecules, 2024 (PubMed: 39362426) [IF=8.2]

Restrictive clause

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.

MMP13 Antibody - #AF5355